Proton Pump Inhibitors Bigger Impact On Dasatinib Efficacy In CML Than Previously Thought Oncology Times - OncTimes Talk podcast

Artwork

Medicine Oncology Cancer Oncology Times Science News Health and Well-Being

Inhoud geleverd door Oncology Times. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Oncology Times of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Oncology Times - OncTimes Talk « »
Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought

5M ago 4:31

Delen

Inhoud geleverd door Oncology Times. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Oncology Times of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden.

Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression.

The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

… continue reading

175 afleveringen

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Artwork

Proton Pump Inhibitors Bigger Impact on Dasatinib Efficacy in CML Than Previously Thought

Oncology Times - OncTimes Talk

22 subscribers

published 5M ago

Delen

Inhoud geleverd door Oncology Times. Alle podcastinhoud, inclusief afleveringen, afbeeldingen en podcastbeschrijvingen, wordt rechtstreeks geüpload en geleverd door Oncology Times of hun podcastplatformpartner. Als u denkt dat iemand uw auteursrechtelijk beschermde werk zonder uw toestemming gebruikt, kunt u het hier beschreven proces https://nl.player.fm/legal volgen.

Although co-medication with proton pump inhibitors (PPI) is not advised for patients being treated with dasatanib for their chronic myeloid leukemia (CML), confirmation that this recommendation is often overlooked has been reported in a study led by Torsten Dahlén, a PhD student at the Karolinska Institutet in Stockholm, Sweden.

Furthermore, the study found a higher than previously reported negative interaction of PPI comedication on crystalline dasatinib bioavailability that may compromise clinical efficacy and risk CML disease progression.

The latest findings from the study were reported in a poster session at the 2024 ASCO Annual Meeting where Oncology Times reporter Peter Goodwin met up with Olof Harlin, PhD, of Xspray Pharma, based in Solna, near Stockholm, Sweden.

… continue reading

175 afleveringen

#Medicine #Oncology #Cancer #Oncology Times #Science #News #Health and Well-Being

Alle afleveringen

×

Welkom op Player FM!

Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.

Luister naar 500+ onderwerpen